Ballysillan Pharmacy Ltd - Period Ending 2022-05-31

Ballysillan Pharmacy Ltd - Period Ending 2022-05-31


Ballysillan Pharmacy Ltd NI046545 false 2021-06-01 2022-05-31 2022-05-31 The principal activity of the company is that of a pharmacy. Digita Accounts Production Advanced 6.30.9574.0 true NI046545 2021-06-01 2022-05-31 NI046545 2022-05-31 NI046545 core:CurrentFinancialInstruments 2022-05-31 NI046545 core:CurrentFinancialInstruments core:WithinOneYear 2022-05-31 NI046545 core:FurnitureFittingsToolsEquipment 2022-05-31 NI046545 core:LandBuildings 2022-05-31 NI046545 bus:SmallEntities 2021-06-01 2022-05-31 NI046545 bus:AuditExemptWithAccountantsReport 2021-06-01 2022-05-31 NI046545 bus:AbridgedAccounts 2021-06-01 2022-05-31 NI046545 bus:SmallCompaniesRegimeForAccounts 2021-06-01 2022-05-31 NI046545 bus:RegisteredOffice 2021-06-01 2022-05-31 NI046545 bus:Director1 2021-06-01 2022-05-31 NI046545 bus:Director2 2021-06-01 2022-05-31 NI046545 bus:PrivateLimitedCompanyLtd 2021-06-01 2022-05-31 NI046545 bus:Agent1 2021-06-01 2022-05-31 NI046545 core:Goodwill 2021-06-01 2022-05-31 NI046545 core:FurnitureFittingsToolsEquipment 2021-06-01 2022-05-31 NI046545 core:LandBuildings 2021-06-01 2022-05-31 NI046545 core:LeaseholdImprovements 2021-06-01 2022-05-31 NI046545 countries:NorthernIreland 2021-06-01 2022-05-31 NI046545 2021-05-31 NI046545 core:FurnitureFittingsToolsEquipment 2021-05-31 NI046545 core:LandBuildings 2021-05-31 NI046545 2020-06-01 2021-05-31 NI046545 2021-05-31 NI046545 core:CurrentFinancialInstruments 2021-05-31 NI046545 core:CurrentFinancialInstruments core:WithinOneYear 2021-05-31 NI046545 core:FurnitureFittingsToolsEquipment 2021-05-31 NI046545 core:LandBuildings 2021-05-31 iso4217:GBP xbrli:pure

Registration number: NI046545

Ballysillan Pharmacy Ltd

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 31 May 2022

 

Ballysillan Pharmacy Ltd

Contents

Company Information

1

Accountants' Report

2

Abridged Balance Sheet

3 to 4

Notes to the Unaudited Abridged Financial Statements

5 to 9

 

Ballysillan Pharmacy Ltd

Company Information

Directors

Mr Ronald Adrian Badger

Mr Darran Lucas

Registered office

34 Dufferin Avenue
Bangor
Down
BT20 3AA

Accountants

Hamilton Morris Waugh
Chartered Certified Accountants
34 Dufferin Avenue
Bangor
Down
BT20 3AA

 

Chartered Certified Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Ballysillan Pharmacy Ltd
for the Year Ended 31 May 2022

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Ballysillan Pharmacy Ltd for the year ended 31 May 2022 as set out on pages 3 to 9 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants (ACCA), we are subject to its ethical and other professional requirements.

This report is made solely to the Board of Directors of Ballysillan Pharmacy Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Ballysillan Pharmacy Ltd and state those matters that we have agreed to state to the Board of Directors of Ballysillan Pharmacy Ltd, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Ballysillan Pharmacy Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Ballysillan Pharmacy Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Ballysillan Pharmacy Ltd. You consider that Ballysillan Pharmacy Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Ballysillan Pharmacy Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Hamilton Morris Waugh
Chartered Certified Accountants
34 Dufferin Avenue
Bangor
Down
BT20 3AA

11 August 2022

 

Ballysillan Pharmacy Ltd

(Registration number: NI046545)
Abridged Balance Sheet as at 31 May 2022

Note

2022
£

2021
£

Fixed assets

 

Intangible assets

4

1

1

Tangible assets

5

6,774

16,937

 

6,775

16,938

Current assets

 

Stocks

6

20,826

21,853

Debtors

1,417,140

423,852

Cash at bank and in hand

 

369,376

1,374,302

 

1,807,342

1,820,007

Prepayments and accrued income

 

983

1,728

Creditors: Amounts falling due within one year

(164,178)

(341,816)

Net current assets

 

1,644,147

1,479,919

Total assets less current liabilities

 

1,650,922

1,496,857

Accruals and deferred income

 

(2,422)

(2,533)

Net assets

 

1,648,500

1,494,324

Capital and reserves

 

Called up share capital

7

100

100

Retained earnings

1,648,400

1,494,224

Shareholders' funds

 

1,648,500

1,494,324

For the financial year ending 31 May 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

Ballysillan Pharmacy Ltd

(Registration number: NI046545)
Abridged Balance Sheet as at 31 May 2022

Approved and authorised by the Board on 11 August 2022 and signed on its behalf by:
 

.........................................
Mr Ronald Adrian Badger
Director

 

Ballysillan Pharmacy Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2022

1

General information

The company is a private company limited by share capital, incorporated in Northern Ireland.

The address of its registered office is:
34 Dufferin Avenue
Bangor
Down
BT20 3AA
Northern Ireland

These financial statements were authorised for issue by the Board on 11 August 2022.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Ballysillan Pharmacy Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2022

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Leasehold improvements

Straight line over 5 years

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight line over 10 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Ballysillan Pharmacy Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2022

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Ballysillan Pharmacy Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2022

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 5 (2021 - 5).

4

Intangible assets

Total
£

Cost or valuation

At 1 June 2021

755,000

At 31 May 2022

755,000

Amortisation

At 1 June 2021

754,999

At 31 May 2022

754,999

Carrying amount

At 31 May 2022

1

At 31 May 2021

1

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 June 2021

67,750

6,278

74,028

At 31 May 2022

67,750

6,278

74,028

Depreciation

At 1 June 2021

50,813

6,278

57,091

Charge for the year

10,163

-

10,163

At 31 May 2022

60,976

6,278

67,254

Carrying amount

At 31 May 2022

6,774

-

6,774

At 31 May 2021

16,937

-

16,937

Included within the net book value of land and buildings above is £6,774 (2021 - £16,937) in respect of long leasehold land and buildings.
 

 

Ballysillan Pharmacy Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 May 2022

6

Stocks

2022
£

2021
£

Finished goods and goods for resale

20,826

21,853

7

Share capital

Allotted, called up and fully paid shares

 

2022

2021

 

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100